Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of tabelecleucel in Epstein-Barr virus-associated diseases
2020-000177-25Phase 2Active
- Sponsor
- Atara Biotherapeutics
- Start
- Aug 2020
- Modality
- Allogeneic CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tabelecleucel in EBV-positive lymphoproliferative disorder (EBV-LPD), EBV-positive primary immunodeficiency lymphoproliferative disease and Epstein-Barr virus-associated diseases, sponsored by Atara Biotherapeutics. Primary endpoint: Objective response rate. Started Aug 2020; status: active.
02
Drugs
tabelecleucel
03
Conditions
EBV-positive lymphoproliferative disorder (EBV-LPD)EBV-positive primary immunodeficiency lymphoproliferative diseaseEpstein-Barr virus-associated diseases
Beyond the preview
Go deeper on 2020-000177-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000177-25.